case study 3 involving merck s crixivan
Resource allocation, scarcity, pricing, and stakeholder involvement are recurring issues in healthcare. The treatment for HIV discussed in this case is no longer groundbreaking; the lessons remain salient. A current example is Gileadâ€™s hepatitis C drug, Sovaldi, that costs $1,000 per pill, or more than $84,000 per patient in a course of treatment. Demand for Sovaldi is high, but its cost causes access problems for many patients. How should a costly, scarce resource be allocated? Does Gilead have a responsibility to increase access to Sovaldi? Merckâ€™s Crixivan offers insight into such issues.